The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| PGEN | +287.3% | -57.78% | -15.84% | -85% |
| S&P | +12.93% | +85.68% | +13.18% | +301% |
Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the following segments: Biopharmaceuticals, Exemplar, and Trans Ova. The Biopharmaceuticals segment is involved in advancing the next generation of gene and cell therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases. It also engages in pioneering a proprietary class of microbe-based biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics. The Exemplar segment is focused on developing research models and services for healthcare research applications. The Trans Ova segment provides bovine reproductive technologies. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.
A once-beleaguered gene-therapy stock just landed a major vote of confidence—and the timing seems anything but accidental.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $2.92M | 206.6% |
| Gross Profit | $1.57M | 519.5% |
| Gross Margin | 53.70% | 92.9% |
| Market Cap | $980.33M | 259.8% |
| Market Cap / Employee | $6.86M | 0.0% |
| Employees | 143 | -29.2% |
| Net Income | -$146.34M | -510.3% |
| EBITDA | -$33.68M | -63.6% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $14.32M | -42.1% |
| Accounts Receivable | $0.58M | 21.1% |
| Inventory | 3.1 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $97.07M | 1938.8% |
| Short Term Debt | $1.12M | 13.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -193.82% | -92.0% |
| Return On Invested Capital | -78.72% | -22.8% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$29.46M | -24.7% |
| Operating Free Cash Flow | -$29.07M | -27.9% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 5.92 | 11.33 | -29.81 | -26.64 | -580.67% |
| Price to Sales | 83.57 | 104.23 | 96.99 | 160.18 | 142.95% |
| Price to Tangible Book Value | 12.77 | 29.25 | -11.23 | -17.55 | -196.54% |
| Enterprise Value to EBITDA | -11.95 | -17.87 | -14.59 | -29.33 | 153.25% |
| Return on Equity | -136.3% | -278.5% | -668.0% | -507.7% | 269.35% |
| Total Debt | $5.50M | $5.42M | $5.15M | $98.19M | 1607.98% |
No podcast episodes available.
PGEN earnings call for the period ending June 30, 2021.
PGEN earnings call for the period ending December 31, 2020.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
